Abstract
Introduction

52
Leprosy is a chronic infectious disease of skin and peripheral nerves and is of special concern 53 because it can progress to peripheral neuropathy and permanent progressive deformity. Despite a 54 marked reduction in the prevalence of leprosy since the implementation of multidrug therapy 55 (MDT), the detection rate of new cases has not shown substantial decline (2) . One explanation is 56 that standard immunological and histological approaches for disease assessment are less effective 57 in the diagnosis of early leprosy and, therefore, disease and transmission can progress. In addition, patients. The BI range is 1 to 6 where 1 is least amount of bacilli detectable and 6 the most.
animal models, where only low numbers of bacteria are used, is very limited. Therefore, there is 75 great need for a rapid and sensitive viability assay for M. leprae.
76
To address this, we developed and characterized two quantitative reverse transcriptase-PCR (qRT-77 PCR) assays to provide new tools for determination of Mycobacterium leprae viability for clinical 78 and experimental purposes. M. leprae sodA mRNA and 16S rRNA were used as the RNA targets 79 for these assays and M. leprae repetitive element (RLEP) DNA was used to determine relative 80 bacterial numbers in the same purified bacterial preparations or from crude biological specimens.
81
The sensitivity and specificity of the assay was examined and their ability to detect the viability in These levels were normalized for bacterial numbers using a previously characterized, DNA-based, 201 real-time PCR assay for the M. leprae-specific repetitive element (RLEP) (29) . Primers and probes 202 were designed using Primer Express 2.0 software, Applied BioSystems (Table 1) . Purified M. values were interpolated automatically for each sample using the standard curve method and normalized using the RLEP data for the same sample. to 5% that of non-treated controls 48 hr post rifampin treatment (Fig. 1A) and that these levels 238 were significantly lower (p < 0.001) than that of 16S rRNA which were reduced to 38% of that of 239 non-treated controls (Fig. 1B) . However, after a week of treatment both were essentially 240 background levels. In addition, reduction of sodA mRNA levels could be observed as early as 241 within 12 hr of rifampin treatment compared to untreated controls (data not shown). (Table   264 2). However, the effects of the different treatments on M. leprae viability were lower when (Table 3) . Moreover, when the BI of patients' skin slit smears were compared to the number of M.
leprae as a function of M. leprae DNA using real-time RLEP PCR, a significant association was 281 observed (r = 0.6942; p = 0.001). Higher DNA concentrations correlated with higher BI values 282 and lower DNA concentrations correlated with lower BIs (Fig. 2) sputa to ascertain whether they could serve as potential markers of response to chemotherapy (4). 
